Synonym
CEACAM1, CD66a, BGP, BGP1, BGPI
Source
Human CEACAM-1, His Tag (CE1-H5220) is expressed from human 293 cells (HEK293). It contains AA Gln 35 - Gly 428 (Accession # AAH14473).
Predicted N-terminus: Gln 35
Request for sequence
Molecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 44.1 kDa. The protein migrates as 57-100 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to different glycosylation.
Endotoxin
Less than 0.1 EU per μg by the LAL method / rFC method.
Purity
>92% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Background
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is also known as Biliary glycoprotein 1 (BGP1), CD66a, which belongs to the immunoglobulin superfamily or CEA family. CEACAM1 /CD66a contains three Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. CEACAM1 /CD66a was described as an adhesion molecule mediating cell adhesion via both homophilic and heterophilic manners, and was detected on leukocytes, epithelia, and endothelia. Studies have revealed that CEACAM1 / BGP-1 performs actions in multiple cellular processes including tissue differentiation, angiogenesis, apoptosis, metastasis, as well as the modulation of innate and adaptive immune responses.
China
